Zanoterone

Zanoterone is an orally active antagonist of the androgen receptor (AR) with a Ki of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth[1].

Product Specifications

CAS Number

[107000-34-0]

Product Name Alternative

WIN 49596

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/zanoterone.html

Solubility

10 mM in DMSO

Smiles

C[C@@]12[C@]3([H])[C@](CC[C@@]1([H])CC4=NN(S(C)(=O)=O)C=C4C2)([H])[C@@]5([H])[C@](CC3)([C@@](O)(CC5)C#C)C

Molecular Formula

C23H32N2O3S

Molecular Weight

416.58

References & Citations

[1]Juniewicz PE, et al. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs. Endocrinology. 1993 Aug;133 (2) :904-13.